• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
Cancer company Achilles Therapeutics Ltd. has launched with a £13.2m ($16.9m) Series A round provided by CRT Pioneer Fund, UCL Technology Fund, and company founders Syncona LLP, Cancer Research UK’s Cancer Research Technology (CRT), UCL Business and the Francis Crick Institute. (Oct.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
